Anti-Hypertensive Drugs - GCC

GCC

Highlights

The Anti-Hypertensive Drugs market in GCC is expected to witness substantial growth in the coming years.
According to projections, the revenue is estimated to reach US$187.20m by 2024.
Furthermore, it is anticipated that the market will exhibit a steady annual growth rate (CAGR 2024-2029) of -0.02%, leading to a market volume of US$187.00m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with an estimated US$12.29bn in 2024.
The demand for anti-hypertensive drugs in the GCC is rising steadily due to the high prevalence of hypertension among the population.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Anti-Hypertensive Drugs market in GCC has been experiencing significant growth in recent years.

Customer preferences: The rising prevalence of hypertension in GCC countries has led to an increase in demand for Anti-Hypertensive Drugs. In addition, the aging population and unhealthy lifestyle habits such as lack of physical activity, smoking, and unhealthy diets have contributed to the growth of the market.

Trends in the market: Saudi Arabia is the largest market for Anti-Hypertensive Drugs in the GCC region, followed by the UAE and Qatar. The market is dominated by branded drugs, with a preference for fixed-dose combination products. However, there is also a growing demand for generic drugs due to their affordability. The market is expected to continue growing due to the increasing prevalence of hypertension and the introduction of new drugs.

Local special circumstances: In GCC countries, there is a high prevalence of obesity, which is a major risk factor for hypertension. This has led to a growing demand for Anti-Hypertensive Drugs in the region. In addition, the GCC region has a high-income population, which has contributed to the growth of the market.

Underlying macroeconomic factors: The healthcare sector in GCC countries is undergoing significant development, with increased investment in healthcare infrastructure and the introduction of health insurance schemes. This has led to improved access to healthcare services and increased demand for drugs, including Anti-Hypertensive Drugs. In addition, the GCC region has a growing population, which is expected to contribute to the growth of the market in the coming years.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.